AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03133611 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Speech assessment
Description: Each subject will undergo short non-invasive speech assessment lasting approximately 15 minutes that will be recorded using microphone.
Study NCT03133611 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Routine clinical assessment
Description: Volunteers who enroll in the study will undergo various assessments lasting about 2 hours, including neurological examination of both motor and non-motor skills, autonomic testing and cognitive testing.
Study NCT03383861 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Dual-Energy X-ray Absorptiometry (DXA)
Description: BMD t-score derived from DXA scan
Study NCT03289208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCI-186
Description: 30 mg of edaravone will be administered intravenously over 60 minutes.
Study NCT01622959 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: -Group Acupuncture: Receiving protocol of acupuncture. Acupuncture is performed by a trained certificied resident.~The protocols, which allow acupuncture points to be selected from a pool of pre-determined points for each condition, provide sufficient standardization to assist replication, yet are flexible enough to allow individualized treatments. These protocols also allow for additional points, such as 'ashi points', to be used at the discretion of the acupuncturist. The location of the points, angle of insertion and depth of insertion were sourced from a popular text 'A Manual of Acupuncture'.~-Group Morphine: Receiving 5mg of morphine followed by intravenous administration of 2,5 mg morphine each 5 min, until VAPS becomes \<30%. Treatment failure is defined as VAPS>30 %, 30min after beginning of the protocol. In this case, analgesic treatment was administered according to the treating physician discretion.
Study NCT01622959 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Acupuncture
Description: -Group Acupuncture: Receiving protocol of acupuncture. Acupuncture is performed by a trained certificied resident.~The protocols, which allow acupuncture points to be selected from a pool of pre-determined points for each condition, provide sufficient standardization to assist replication, yet are flexible enough to allow individualized treatments. These protocols also allow for additional points, such as 'ashi points', to be used at the discretion of the acupuncturist. The location of the points, angle of insertion and depth of insertion were sourced from a popular text 'A Manual of Acupuncture'.~-Group Morphine: Receiving 5mg of morphine followed by intravenous administration of 2,5 mg morphine each 5 min, until VAPS becomes \<30%. Treatment failure is defined as VAPS>30 %, 30min after beginning of the protocol. In this case, analgesic treatment was administered according to the treating physician discretion.
Study NCT05627973 — intervention group
Intervention type: DEVICE
Intervention: Aortic Valve Replacement
Description: Surgical replacement of aortic valves
Study NCT02195908 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: single point Neiguan(PC6) plus antiemetic drug
Study NCT02195908 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: single point Zhongwan(CV12) plus antiemetic drug
Study NCT02195908 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: matching points Neiguan(PC6) and Zhongwan(CV12) plus antiemetic drug
Study NCT02195908 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: only antiemetic drug
Study NCT04264858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunoglobulin of cured patients
Description: 0.2g/kg, ivdrip, once a day, for 3 days
Study NCT04264858 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: γ-Globulin
Description: 0.2g/kg, ivdrip, once a day, for 3 days
Study NCT00434408 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: chx once
Description: 4.0% chlorhexidine cleansing of the cord applied once by a project worker visiting the newborn in the home as soon as possible after birth
Study NCT00434408 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHX x 7 days
Description: 4.0% chlorhexidine cleansing of the cord during home visits by project workers for the first 7 days after birth
Study NCT00434408 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: dry cord care
Description: Household members are instructed to apply nothing to the newborn's umbilical cord stump.
Study NCT02976298 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: transcranial magnetic stimulation
Description: comparison of different conditions of transcranial magnetic stimulation
Study NCT00453895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: 50mg Sunitinib
Study NCT03520881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pediatric ASTHMA-Educator mobile application
Description: This intervention represents a mobile application (accessible by iOS and Android devices) that provides asthma education through games and videos.
Study NCT00822614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl TAIFUN
Description: Inhalation of Fentanyl via TAIFUN inhaler
Study NCT00822614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid
Description: Current optimized BTP treatment
Study NCT04412759 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: microbial cellulose
Description: polymer dressing synthesized in abundance with Acetobacter Xylinum
Study NCT03206762 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Jetstream Atherectomy with randomization to the Ranger or IN.PACT DCB Arm or the POBA+DCB (Ranger or IN.PACT) Arm
Description: Jetstream Atherectomy with randomization to the Ranger or IN.PACT DCB Arm or the POBA+DCB (Ranger or IN.PACT) Arm
Study NCT03592901 — intervention group
Intervention type: DRUG
Intervention: brachial plexus anesthesia
Description: Anesthesia to some part of the brachial plexus prior to surgery. Patients are already receiving this regardless of participation in study.
Study NCT02754986 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Analysis of the holter electrocardiogram
Study NCT02032979 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychiatric test
Study NCT02703090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Study NCT02703090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Study NCT04390854 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood clot scaffold
Description: Bleeding will be induced in the canal by passing a size 30 sterile K-file 3 mm beyond the apex with the goal of having the entire canal filled with blood to the level of the cemento-enamel junction. Bleeding will be stopped just below the cemento enamel junction.~Biodentine will be placed approximately 3-4 mm below the cementoenamel junction.
Study NCT02691533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ω3 PUFA (Polyunsaturated fatty acids) (10% Omegavan 100 ml)
Study NCT02691533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ω6 PUFA (Polyunsaturated fatty acids) (10% Intralipid 100 ml)
Study NCT04390854 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood clot scaffold combined with PRF
Description: Platelet-rich fibrin will be prepared by drawing the patient blood into a 10mL test tube without the addition of an anticoagulant. To prevent the blood from coagulating after coming in contact with the glass tube, it will be centrifuged immediately using a table top centrifuge\*\* at 400 g force for 12 minutes. Then platelet-rich fibrin membrane will be placed into the canal space to a level 3 mm below the cemento-enamel junction using hand plugger following the induction of apical bleeding by passing a number 30 sterile hand file 3 mm beyond the apex of the tooth. Biodentine cap will be placed over the platelet-rich fibrin scaffold.
Study NCT02584140 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Text Messaging
Description: All participants assigned to the iTAB intervention will receive daily dosing reminders that will be sent for the first 6 weeks and then continue with reminders for the duration of the study.
Study NCT02584140 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Adherence Counseling
Description: All participants assigned to the counseling intervention will receive sexual health and medication adherence counseling at each study visit. Participants with suboptimal adherence (TFV-DP levels of \<1050 fmol/punch (representing fewer than mean 6-7 daily doses per week)) will trigger a targeted iNSC session. Participants with two TFV-DP levels of \<1050 fmol/punch will trigger PrEP Steps, a higher intensity adherence counseling intervention consisting of four 50-minute counseling sessions and 2 booster counseling sessions.
Study NCT02584140 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Daily Oral PrEP
Description: All participants will be offered daily oral emtricitabine/tenofovir disoproxil fumarate for Pre-exposure Prophylaxis.
Study NCT02012309 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV-13
Study NCT02012309 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PPSV-23
Study NCT01447264 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Land exercises
Description: 3 times a week. 50 minutes in every session. Performed by educational professor
Study NCT01447264 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Water exercises
Description: 3 times a week. 50 minutes in every session. Performed by educational professor
Study NCT00599209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinical decision support
Description: CDS is provided to prescribers on intervention units upon ordering medication which offers advice on prescribing and monitoring practices
Study NCT02470559 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given SC
Study NCT03002961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBP-6000
Description: single dose of RBP-6000, preceded by a pharmacokinetic (PK) sample followed by serial PK samples post-dose. Additionally subjects to remain in the clinic through Day 21 for safety assessments
Study NCT03002961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suboxone
Description: RBP-6000 injection after 7 days of SL Suboxone administration. Interventions as above with additional daily PK collections during Suboxone treatment prior to RBP-6000 administration
Study NCT02847962 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Corn Soy Blend Plus (CSB+)
Study NCT02691533 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: No Lipid Emulsion/Placebo
Study NCT04059653 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Description: Electrical stimulation device
Study NCT04059653 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: GP treatment as usual
Study NCT03271554 — intervention group
Intervention type: DRUG
Intervention: Alectinib
Description: According to local labeling the recommended dose of alectinib is 600 mg given orally, twice daily with food (total daily dose of 1200 mg).
Study NCT02878902 — intervention group
Intervention type: OTHER
Intervention: Post implementation
Description: Patient group whose care course was organized by the nurse coordinator of chronic renal failure
Study NCT02847962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Corn Soy Blend 14 (CSB14)
Study NCT03587051 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low glycemic index post-exercise diet
Description: Feeding of a low-glycemic index, lentil meal after 90 minutes of walking exercise
Study NCT03587051 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High glycemic index post-exercise diet
Description: Feeding of a high-glycemic index meal (i.e. instant mashed potatoes, white bread, egg whites) after 90 minutes of walking exercise
Study NCT02842827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bomedemstat
Description: oral administration
Study NCT02847962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White Sorghum Cowpea Blend Variety 1
Study NCT02847962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White Sorghum Cowpea Blend Variety 2
Study NCT02847962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red Sorghum Cowpea Blend
Study NCT02847962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White Sorghum Soy Blend
Study NCT02961608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug conversion from Tacrolimus (Prograf® or Adoport®) to LCP-Tacrolimus (Envarsus®)
Description: Drug conversion from Tacrolimus (Prograf® or Adoport®) to LCP-Tacrolimus (Envarsus®)
Study NCT03605667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: troriluzole
Description: Oral BHV-4157 will be given daily for up to 48 weeks
Study NCT03605667 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Oral matching placebo will be given daily for up to 48 weeks
Study NCT04361435 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Chest physiotherapy using a non-invasive oscillating device
Description: NIOD will be implemented on four different parts of the chest walls, 3 minutes for each part and 12 minutes in total per each session. Left and right front and posterior chest walls will be stimulated, particularly, on the anterior chest, intercostal spaces 1-2 above nipple line and lateral side of the mid-clavicular line 1-2 below intercostal spaces. The intensity of the NIOD can be selected between 80-100%, which is pre-specified on the machine.
Study NCT02337413 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene glycol 3350
Description: Patients will initially receive three days of high dose PEG3350 treatment (1.5gr/kg up to 100gr maximum) and then will be stepped down to 0.8gr/kg subsequently and tapered accoriding to stool consistency and frequency.
Study NCT02337413 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Constipation behavioral therapy
Description: Patients in the active group will receive dietary instruction as to fiber content, as well as behavioral therapy including active sitting on the toilet to attempt defaction following meals.
Study NCT02337413 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Urotherapy
Description: Patients will be guided for appropriate drinking and toilet habits, and will start with timed voiding.
Study NCT02337413 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Urotherapy
Description: Patients will be guided for appropriate drinking and toilet habits, and will start with timed voiding.
Study NCT03380650 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: directional atherectomy and locol drug delivery
Description: combined use of directional atherectomy and locol drug delivery for the treatment of femoralpopliteal disease
Study NCT03380650 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: drug-coated balloon dilation
Description: use of drug-coated balloon dilation for the treatment of femoralpopliteal disease
Study NCT01769313 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser-assisted cataract surgery
Description: The anterior capsulotomy and lens fragmentation will be performed by means of femtosecond laser surgery
Study NCT01769313 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manually performed cataract surgery
Description: The anterior capsulotomy and lens fragmentation will be performed manually.
Study NCT02981147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phytus (Cisti, Thyme and Ivy Leaves)
Description: Phytus is a medicinal herb containing Ivy leaves, Cisti and Thyme.
Study NCT00149968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric-Coated Mycophenolate Sodium (EC-MPS)
Description: Patient on MMF treatment completes questionnaire and switch to equimolar doses of Myfortic. Maximum daily dose 1440 mg
Study NCT04827264 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Safe Return to Play Following ACL Reconstruction Checklist
Description: All participants who have undergone primary ACL reconstruction will receive PT evaluation using our Return to Play Checklist at 7 months post-op, prior to return to sports
Study NCT00584948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Week 1: Take 5mg tab every morning. Week 2: Take 5mg tab every morning and evening. Week 3: Take 10mg tab in the morning and 5 mg in the evening. Week 4: Take 10 mg tab in the morning and evening, and remain on this dose through the remainder of the study.
Study NCT00584948 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Week 1: Take 5mg tab every morning. Week 2: Take 5mg tab every morning and evening. Week 3: Take 10mg tab in the morning and 5 mg in the evening. Week 4: Take 10 mg tab in the morning and evening, and remain on this dose through the remainder of the study.
Study NCT04604535 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Concentrated beetroot juice
Description: 70mL concentrated beetroot juice (400mg nitrate)
Study NCT04604535 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 70mL concentrated nitrate deplete beetroot juice (\<0.01mmol/L nitrate)
Study NCT03444610 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood transfusion escalation rate
Description: 3+3 dose escalation (3 patients/cohort) each started on a fixed rate (standard is 5 ml/kg/ hr).1st cohort start at 6ml/kg/hr till complete prescribed volume. Rate escalation by 1ml/kg/each cohort until dose limiting toxicities (DLTs) or max of 10ml/kg/hr. If no DLTs new cohort enrolled at the next planned rate. If DLTs seen in 1 patient in the cohort, another 3 patients treated with the same dose level.1ry phase I end point is maximum-tolerated rate (MTR) of blood transfusion that can be infused safely ( max rate at which 1 or fewer of 3 patients experienced DLT) or dose of 10ml/kg/hr. DLT is transfusion related adverse event lead to stop of transfusion. MTR is highest dose at which no more than 1of 6 patients experienced a DLT.15 additional patients enrolled at MTR to confirm safety.
Study NCT02931617 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chest Physiotherapy
Study NCT02931617 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chest Physiotherapy
Study NCT02931617 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Post-therapy lung volume measurements
Description: In both intervention groups.
Study NCT02931617 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Post-therapy lung volume measurements
Description: In both intervention groups.
Study NCT00751686 — intervention group
Intervention type: PROCEDURE
Intervention: Stool sample
Description: Collection of the stool at least 48 hours after hospitalisation. Stool samples should be obtained preferably within 4 and no later than 10 days after the onset of the GE symptoms.
Study NCT00751686 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Logbook, Health Economic Questionnaire, Telephone call.
Study NCT00879021 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lyrica
Description: study participants will start will be on 150mg of Pregabalin or placebo capsules by mouth , twice a day.They will be on drug approx. 49 weeks and followed for another 49 weeks after stopping the medication.
Study NCT00879021 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo
Description: 150 mg by mouth ,twice a day for 49 weeks
Study NCT02336282 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: transcranial Direct Current Stimulation (tDCS) involves modulation of cerebral cortex excitability by the application of weak direct current to the scalp. tDCS is a technique that applies safe, low level direct current through large pads on the scalp to stimulate the underlying brain region, with current level \< 0.10 C/cm2. Direct current is transferred by a pair of saline-soaked sponges from the anode to the cathode.
Study NCT02336282 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham
Description: The sham intervention will be used in both arms with one arm receiving the sham intervention on day 1 and the other receiving the sham intervention on day 2. The sham procedure provides the same small current during ramp up to imitate the intervention, but the current is discontinued after ramp up and no intervention is provided. Direct current is transferred by a pair of saline-soaked sponges from the anode to the cathode.
Study NCT02336282 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Assessment
Description: Three tests will be used to evaluate cognitive function: Dimensional Change Card Sort Test, Flanker Inhibitory Control and Attention Test, and List Sorting Working Memory Test. These measures have a computerized format and are nationally standardized.~The Gray Oral Reading Test measures reading comprehension. Participants are asked to read a set of passages and recall specific details from the stories.~The Woodcock Johnson Understanding Directions measures listening comprehension. Participants listen to a series of complex instructions, then follow the directions by pointing to various objects in a colored picture.